Welcome to our dedicated page for Ispecimen SEC filings (Ticker: ISPC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
iSpecimen Inc. filings document material events, governance matters, capital-structure changes, and reporting status for the company’s Nasdaq-listed common stock. Recent 8-K disclosures cover the completed 1-for-40 reverse stock split, related certificate amendments, Regulation FD press-release exhibits, shareholder meeting adjournments, and board composition changes.
The company’s regulatory record also includes emerging growth company disclosures and a Rule 12b-25 notice tied to its annual report filing process. These filings provide formal records of iSpecimen’s public-company obligations alongside its biospecimen marketplace operations.
iSpecimen Inc. is pursuing a primary, best‑efforts equity offering of up to 2,092,050 shares of common stock, Pre‑Funded Warrants to purchase up to 2,092,050 shares, and up to 2,092,050 underlying shares, for aggregate gross proceeds of up to $5,000,000. The assumed price is $2.39 per Share, matching the July 14, 2026 Nasdaq close.
Common stock outstanding was 1,522,359 shares as of July 14, 2026 and would increase to up to 3,614,409 shares if the full offering is sold and all Pre‑Funded Warrants are exercised. Each Pre‑Funded Warrant costs $2.3899, is exercisable at $0.0001 per share, and is subject to 4.99% (or 9.99% on notice) beneficial‑ownership caps.
Assuming all Shares are sold and no Pre‑Funded Warrants are issued, net proceeds are estimated at approximately $4,680,000, to be used for fees and expenses, repayment of outstanding debt, potential asset or business acquisitions, marketing and advertising (including up to $1,100,000 for IR Agency LLC), and general corporate and working capital needs. For 2025, revenue was $1,928,998 with a net loss of $10,487,532; for the quarter ended March 31, 2026, revenue was $156,009 and net loss $2,275,221. As of March 31, 2026, cash was $2,818,989, working capital was negative $2,115,634, and the company reported substantial doubt about its ability to continue as a going concern.
iSpecimen Inc. completed Milestone 3 in its digital transformation program powered by SalesStack Solutions on July 9, 2026. Under Section 3.1 of the Definitive Software Purchase and Services Agreement with Sales Stack Solutions Corp., the company made a $700,000 payment upon completion.
Milestone 3 delivers additional marketplace features, a broader geographic rollout, and deeper integrations with partner ecosystems, building on the system integration and marketplace activation delivered in Milestone 2. The company had previously disclosed the completion of Milestones 1 and 2 under the same agreement.
iSpecimen Inc. has filed an amended S-1 to register up to 1,515,152 shares of common stock, up to 1,515,152 pre-funded warrants, and 1,515,152 shares issuable upon warrant exercise in a best-efforts offering capped at $4,000,000.00.
The assumed price is $2.64 per share, matching the July 2, 2026 Nasdaq close for ISPC, with each pre-funded warrant priced at $2.6399 and carrying a $0.0001 exercise price. If all shares are sold, net proceeds are estimated at about $3.72M, earmarked for fees and expenses, non‑interest‑bearing outstanding liabilities, up to $700,000 for potential acquisitions, up to $1,000,000 for marketing with IR Agency LLC, and general working capital.
The company reverse‑split its stock 1‑for‑40 in April 2026 and had 1,522,359 shares outstanding as of July 2, 2026, rising to a maximum of 3,440,599 shares if the offering and warrant exercises are fully completed. iSpecimen’s 2025 revenue was $1,928,998 with a net loss of $10,487,532; Q1 2026 revenue was $156,009 with a net loss of $2,275,221. As of March 31, 2026, cash was $2,818,989 and working capital was negative $2,115,634, and auditors highlighted substantial doubt about the company’s ability to continue as a going concern.
iSpecimen Inc. is registering up to 1,544,402 shares of common stock and related pre-funded warrants in a best-efforts offering. At an assumed price of $2.59 per share, the potential raise is up to $4.0 million, with common shares outstanding rising from 1,437,157 to as many as 2,981,559.
The company plans to use net proceeds for placement agent fees, debt repayment, potential acquisitions, up to $1.0 million of marketing and advertising (including services from IR Agency LLC), and general working capital. iSpecimen operates an online biospecimen marketplace but remains loss-making, with a going concern warning, an accumulated deficit of $84.6 million, limited cash of $2.8 million, and a working capital deficit.
iSpecimen Inc. registers 488,290 shares of Common Stock for resale by selling stockholders. This prospectus covers up to 488,290 shares of common stock consisting of 85,202 Shares issued in the May 2026 Private Placement and 403,088 Warrant Shares issuable upon exercise of Pre-Funded Warrants, to be offered and resold from time to time by the selling stockholders. The Company will not receive proceeds from these resales; it may receive nominal proceeds (approximately $40.00) only if the Pre-Funded Warrants are exercised for cash at $0.0001 per share. The shares registered may be sold in public or private transactions at prevailing or negotiated prices; timing and amounts of any sales are determined by the selling stockholders.
iSpecimen Inc. received a Nasdaq notice that it no longer meets the exchange’s stockholders’ equity requirement for continued listing. Nasdaq Listing Rule 5550(b)(1) requires at least $2,500,000 in stockholders’ equity, while the company reported $814,038 as of March 31, 2026.
The company also does not meet Nasdaq Capital Market alternative standards based on equity, market value of listed securities, or net income. iSpecimen’s common stock will continue trading on the Nasdaq Capital Market under the symbol ISPC while it works on a plan.
The company has 45 calendar days from the May 29, 2026 notice to submit a compliance plan, and Nasdaq may grant up to 180 calendar days from that date to demonstrate compliance. The company intends to submit a plan but there is no assurance it will be accepted or that compliance will be regained.
iSpecimen Inc. reported the results of its reconvened 2025 Annual Meeting of Stockholders held on May 29, 2026. Of 8,478,579 common shares eligible to vote as of November 3, 2025, 2,979,059 shares were present or represented by proxy, establishing a quorum of approximately 35.14%.
Stockholders elected Arphing (Tommy) Lee as a Class I director for a three-year term, with 562,361 votes for and 150,431 withheld, and 2,266,267 broker non-votes. They also ratified Bush & Associates CPA LLC as independent registered public accounting firm for the year ending December 31, 2025, by 2,424,420 votes for, 155,256 against, and 399,383 abstentions.
In addition, stockholders approved the iSpecimen Inc. 2025 Stock Incentive Plan, receiving 461,073 votes for, 186,740 against, 64,979 abstentions, and 2,266,267 broker non-votes. These outcomes confirm the company’s proposed director slate, auditor, and equity incentive plan for 2025.
iSpecimen Inc. reported a challenging quarter for the period ended March 31, 2026. Revenue fell to $156,009 from $1,057,510 a year earlier, while total operating expenses were essentially flat at $2,694,412, leading to a larger operating loss of $2,538,403. Net loss widened to $2,275,221 compared with $1,658,396 in the prior-year quarter.
Cash and cash equivalents declined to $2,818,989 from $6,880,835 at year-end, driven by operating cash outflows of $3,361,846 and $700,000 invested in internally developed software. The company ended the quarter with total assets of $6,609,658, liabilities of $5,795,620, and stockholders’ equity of $814,038.
The filing states there is substantial doubt about iSpecimen’s ability to continue as a going concern, citing negative working capital of $2,115,634, an accumulated deficit of $84,625,370, and significant accounts payable and accrued expenses. Management has reduced workforce and technology spending by roughly 70% and 36%, respectively, versus the prior-year quarter and continues to pursue cost cuts and revenue growth.
The company executed or planned multiple financing steps, including prior underwritten and private placements, issuance and partial conversion of Series C preferred stock, and a subsequent May 2026 equity raise of 488,281 common shares or pre-funded warrants at $5.12 per share. It also implemented reverse stock splits of 1-for-20 in 2024 and 1-for-40 effective April 27, 2026 to maintain Nasdaq listing compliance. The quarter included ongoing sales tax remediation efforts, resolution of some legal matters through settlements, and continuing litigation with several counterparties.
iSpecimen Inc. notified the SEC that its Form 10-Q for the period ended March 31, 2026 will be filed late under Form 12b-25. The notification is dated May 15, 2026.
The company states the delay relates to items described in Part III and expects to file within the permitted cure period under Rule 12b-25; it includes a forward-looking statement disclaimer and is signed by CEO Katharyn Field.